Literature DB >> 14680081

Longitudinal changes in the nature, severity and frequency of COPD exacerbations.

G C Donaldson1, T A R Seemungal, I S Patel, S J Lloyd-Owen, T M A Wilkinson, J A Wedzicha.   

Abstract

Exacerbations are an important feature and outcome measure in chronic obstructive pulmonary disease (COPD), but little is known about changes in their severity, recovery, symptom composition or frequency over time. In this study 132 patients (91 male; median age 68.4 yrs and median forced expiratory volume in one second (FEV1) 38.4% predicted) recorded daily symptoms and morning peak expiratory flow. Patients were monitored for a median of 918 days and 1,111 exacerbations were identified. Patients with severe COPD (Global Initiative for Chronic Obstructive Lung Disease (GOLD) category III, n=38) had an annual exacerbation frequency of 3.43 x yr(-1), 0.75 x yr(-1) higher than those with moderate COPD (GOLD II, n=94). Exacerbation frequency did not change significantly during the study. At exacerbation onset, symptom count increased to 2.23, relative to a baseline of 0.36 set 8-14 days previously, and this increase rose by 0.05 x yr(-1). Recovery to baseline levels in symptoms and FEV1 took longer (0.32 and 0.55 days x yr(-1)). Sputum purulence at exacerbation became more prevalent over time by 4.1% x yr(-1) from an initial value of 17%. The results of this study suggest that over time, individual patients have more symptoms during exacerbations, with an increased chance of sputum purulence and longer recovery times.

Entities:  

Mesh:

Year:  2003        PMID: 14680081     DOI: 10.1183/09031936.03.00038303

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  63 in total

Review 1.  COPD exacerbations. 4: Prevention.

Authors:  S Scott; P Walker; P M A Calverley
Journal:  Thorax       Date:  2006-05       Impact factor: 9.139

2.  The Short-term Impact of Symptom-defined COPD Exacerbation Recovery on Health Status and Lung Function.

Authors:  Lindsey T Murray; Nancy K Leidy
Journal:  Chronic Obstr Pulm Dis       Date:  2018-01-24

3.  Antioxidants of therapeutic relevance in COPD from the neotropical blueberry Anthopterus wardii.

Authors:  Gema Flores; Keyvan Dastmalchi; Abdoulaye J Dabo; Kathleen Whalen; Paola Pedraza-Peñalosa; Robert F Foronjy; Jeanine M D'Armiento; Edward J Kennelly
Journal:  Food Chem       Date:  2012-03-01       Impact factor: 7.514

4.  Oxidative stress and airway inflammation in severe exacerbations of COPD.

Authors:  E M Drost; K M Skwarski; J Sauleda; N Soler; J Roca; A Agusti; W MacNee
Journal:  Thorax       Date:  2005-04       Impact factor: 9.139

5.  Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.

Authors:  E F M Wouters; D S Postma; B Fokkens; W C J Hop; J Prins; A F Kuipers; H R Pasma; C A J Hensing; E C Creutzberg
Journal:  Thorax       Date:  2005-06       Impact factor: 9.139

Review 6.  The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD.

Authors:  Barbara P Yawn; Ibrahim Raphiou; Judith S Hurley; Anand A Dalal
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-06-03

Review 7.  Chronic obstructive pulmonary disease: the clinical management of an acute exacerbation.

Authors:  J R Hurst; J A Wedzicha
Journal:  Postgrad Med J       Date:  2004-09       Impact factor: 2.401

Review 8.  Pathogen-directed therapy in acute exacerbations of chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez
Journal:  Proc Am Thorac Soc       Date:  2007-12

Review 9.  Newer fluoroquinolones in the treatment of acute exacerbations of COPD.

Authors:  Amit Patel; Robert Wilson
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

Review 10.  Targeted treatment in COPD: a multi-system approach for a multi-system disease.

Authors:  David Anderson; William Macnee
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.